- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SNM Image of the Year: Bi-213-DOTATOC
SNM’s 2012 Image of the Year shows the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of GEP-NETs that do not respond to beta therapy.
The Society of Nuclear Medicine’s 2012 Image of the Year shows the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that do not respond to beta therapy.
Researchers at the annual meeting this week selected this image from more than 2,000 studies.The annual selection demonstrates the most cutting-edge nuclear medicine or molecular imaging research, SNM said. “The images illustrating the effectiveness of Bi-213-DOTATOC for GEP-NETs show the remarkable results that can be achieved in a clinical setting,” said Peter Herscovitch, MD, chair of SNM’s Scientific Program Committee. “This opens up a new door for those patients whose GEP-NETs do not respond to more standard radiotherapy.”
GEP-NETs are rare, slow-growing tumors that are often resistant to standard chemotherapy. In this study, a Bi-213-DOTATOC was synthesized using a microwave-assisted labeling protocol. Twenty-one patients who had previously shown a resistance to treatment with Y-90 or Lu-177-DOTATOC were treated with escalating doses of the peptide receptor alpha-therapy - from 1-10 GBq up to 21 GBq. Researchers assessed response with Ga-68-DOTATOC PET/CT, contrast-enhanced sonography, MRI, digital subtraction angiography, and tumor markers. In addition, markers for hematologic, kidney and endocrine toxicity were monitored during and after treatment, according to the organization.
The labeling protocol for Bi-213-DOTATOC provided reliable doses of the treatment at a clinical level. Patients tolerated the increasing doses well, and there was no acute kidney, endocrine or hematologic toxicity. Researchers observed shrinkage of primary tumors as well as liver and bone metastases, according to SNM.
Alfred Morgenstern, PhD, project leader of the Alpha-Immunotherapy Project at the European Commission, Joint Research Centre, Institute for Transuranium Elements in Karlsruhe, Germany is the lead author of the study.
Responses to Bi-123 DOTANOC treatment observed in patients with tumors resistant to previous treatment with Y-90 or Lu-177-DOTATOC:
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
